EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders

Sandeep Bindra, T M Rangarajan iD, Della Grace Thomas Parambi iD, Sandeep Kumar iD, Jasha Momo H Anal iD, Bijo Mathew iD

ChemMedChem · 28.10.2026 · 21 (20)

DOI: 10.1002/cmdc.70521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 13.10.2026. Verfasst von Sandeep Bindra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Nervous System Diseases, Cholinesterase Inhibitors, Neuroprotective Agents. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurological disorders such as Alzheimer's disease, Parkinson's disease, and neuroinflammatory conditions involve complex, interconnected mechanisms, including neuroinflammation, oxidative stress, cholinergic dysfunction, and synaptic impairment. The cannabinoid type‐2 receptor (CB2R), primarily expressed in immune and glial cells, has emerged as a promising therapeutic target due to its role in modulating neuroinflammation and providing neuroprotection without the psychoactive effects associated with CB1R activation. Recent research highlights the potential of dual‐acting CB2R ligands that also modulate CB1R, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE), offering a multitarget approach to neurological disorders. Although CB1R expression was identified in 1993, significant progress in designing receptor modulators began in the 2000s, with recent focus expanding to autoimmune, metabolic, and cancer‐related applications. This review summarizes advances in the design, synthesis, and structure–activity relationships of CB2R‐targeting ligands, emphasizing dual‐ or multitarget agents with cholinesterase inhibitory activity. Key chemical scaffolds include synthetic cannabinoids, heterocyclic compounds, and hybrid molecules integrating cholinesterase pharmacophores. Molecular docking and in silico studies are discussed to elucidate ligand–receptor interactions, binding modes, and determinants of selectivity. Overall, CB2R‐centric dual‐acting ligands represent a promising strategy for addressing multifactorial neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB2Nervous System DiseasesCholinesterase InhibitorsNeuroprotective AgentsCannabinoidsHumansStructure-Activity RelationshipLigandsAnimalsMolecular Structure

Stichwörter der Autor:innen

Alzheimer's diseaseParkinson's diseaseacetylcholinesterasebutylcholinestrasecannabinoid type‐2 receptorstructure–activity relationships

Substanzen

Receptor, Cannabinoid, CB2LigandsCholinesterase InhibitorsNeuroprotective AgentsCannabinoids

Autor:innen und Institutionen

  • Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India.
  • Department of Chemistry, Sri Venkateswara College, University of Delhi, New Delhi, India.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Aljouf, Saudi Arabia.
  • School of Pharmacy & DST-FIST, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.

ORCID-Profile: T M Rangarajan, Della Grace Thomas Parambi, Sandeep Kumar, Jasha Momo H Anal, Bijo Mathew

Zitieren

APA

Bindra, S., Rangarajan, T. M., Parambi, D. G. T., Kumar, S., Anal, J. M. H., & Mathew, B. (2026). Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70521

Vancouver

Bindra S, Rangarajan TM, Parambi DGT, Kumar S, Anal JMH, Mathew B. Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70521

BibTeX
@article{Bindra2026,
  author = {Bindra, Sandeep and Rangarajan, T M and Parambi, Della Grace Thomas and Kumar, Sandeep and Anal, Jasha Momo H and Mathew, Bijo},
  title = {Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {20},
  doi = {10.1002/cmdc.70521}
}
Kostenlos starten →